Nm Tukhvatulina

Nm Tukhvatulina

Auto-generated profile, based on publicly available information

Nm Tukhvatulina

National Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health of Russian Federation

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2019 in Bulletin of Russian State Medical University
Verified
Journal Article
Open access
ISInna Shuliakova
Inna Shuliakova
Amir I. TukhvatulinAmir I. Tukhvatulin
Amir I. Tukhvatulin
AGAs Gromova
As Gromova
DGDm Grousova
Dm Grousova
NTNm Tukhvatulina
Nm Tukhvatulina
AGAL Gintsburg
AL Gintsburg
Ebola virus disease (EVD) is one of the deadliest viral infections affecting humans and nonhuman primates. Of 6 known representatives of the Ebolavirus genus responsible for the disease, 3 can infect humans, causing acute highly contagious fever characterized by up to 90% fatality. These include Bundibugyo ebolavirus (BDBV), Zaire ebolavirus (ZEBOV) and Sudan ebolavirus (SUDV). The majority of the reported EVD cases are caused by ZEBOV. Vaccine development against the virus started in 1976, immediately after the causative agent of the infection was identified. So far, 4 vaccines have been approved. All of them are based on the protective epitope of the ZEBOV glycoprotein GP. Because SUDV and BDBV can also cause outbreaks and epidemics, it is vital to design a vaccine capable of conferring protection against all known ebolaviruses posing a threat to the human population. This article presents systematized data on the structure, immunogenicity and protective properties of ebolavirus glycoprotein GP, looks closely at the immunodominant epitopes of ZEBOV, SUDV and BDBV glycoprotein GP required to elicit a protective immune response, and offers a rational perspective on the development of a universal vaccine against EVD that relies on the use of vectors expressing two variants of GP represented by ZEBOV and SUDV.

21 August 2024 in medRxiv
Verified
Preprint
Open access
PDF file
DLDy Logunov
Dy Logunov
ISInna Shuliakova
Inna Shuliakova
MBMy Boiro
My Boiro
AMAnna V. Mamatkulova
Anna V. Mamatkulova
ADAlina Dzharullaeva
Alina Dzharullaeva
TGthe GamEvac-Combi trial group
the GamEvac-Combi trial group
Ebola virus disease (EVD) is one of the most dangerous and lethal diseases affecting humans. There are several licensed vaccines against EVD, but it remains one of the priority diseases for research and development of effective vaccines. A double-blind randomized placebo-controlled trial was performed to evaluate safety and immunogenicity of rVSV- and rAd5-vectored vaccine “GamEvac-Combi” in healthy adults of both sexes between 18 and 60 years. Safety and immunogenicity were assessed during the observation period of 12 months. Immunogenicity was assessed with GP-specific ELISA, IFN-γ ELISA, and plaque pseudoneutralization assay. Vaccinated participants showed marked GP-specific IFN-γ response at day 28 and neutralizing response at day 42 (GMT = 32.6, seroconversion rate 96.3%). GP-specific IgG antibody levels in vaccinated participants peaked at day 42 (GMT = 9345) and persisted for a year after vaccination (GMT = 650). The vaccine showed favorable safety profile and induced robust cell-mediated immune response and strong humoral immune response that lasts at least for a year from the start of vaccination. The study was funded by the Ministry of Health of Russian Federation; GamEvac-Combi ClinicalTrials.gov number, NCT03072030 , Pan African Clinical Trial Registry PACTR201702002053400.